{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:43:39Z","timestamp":1790689419612,"version":"4.1.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Health and Medical Research Council of Australia","award":["APP1053206"],"award-info":[{"award-number":["APP1053206"]}]},{"name":"National Health and Medical Research Council of Australia","award":["APP2001692"],"award-info":[{"award-number":["APP2001692"]}]},{"name":"National Health and Medical Research Council of Australia","award":["APP1107178"],"award-info":[{"award-number":["APP1107178"]}]},{"name":"National Health and Medical Research Council of Australia","award":["APP1108422"],"award-info":[{"award-number":["APP1108422"]}]},{"name":"National Health and Medical Research Council of Australia","award":["APP1196492"],"award-info":[{"award-number":["APP1196492"]}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["2021\/ATRG2028"],"award-info":[{"award-number":["2021\/ATRG2028"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The international consensus to revise non-alcoholic fatty liver disease to metabolic (dysfunction)-associated fatty liver disease (MAFLD) in 2020 attracted significant attention. The impact of the MAFLD definition on the research community has not been objectively assessed. We conducted an analysis of systematically collected literature on MAFLD to understand its research impact.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From PubMed, Web of Science, and Scopus, the literature adopting MAFLD, written in English, and published from 2020 to 10 October 2023 was collected. The publication metrics, including publication counts, publishing journals, author countries, author keywords, and citation information, were analyzed to evaluate the research impact and key topics on MAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>1469 MAFLD-related papers were published in 434 journals with a steady increase in the number. The intense publishing and citations activity on MAFLD indicates the large impact of the redefinition. Topic assessment with keyword and citation analysis revealed a transition from the proposal and discussion of the redefinition to clinical characterization of MAFLD with a focus on metabolic dysfunction. Moreover, the diagnostic criteria for MAFLD showed better performance in predicting hepatic and extrahepatic outcomes compared to NAFLD. The publications were from 99 countries with evidence of strong regional and global collaboration. Multiple international societies and stakeholders have endorsed MAFLD for its utility in clinical practice, improving patient management and promoting multidisciplinary care, while alleviating stigma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This survey provides a quantitative measure of the considerable international impact and contributions of the MAFLD definition towards liver research and as part of the spectrum of cardiometabolic disorders.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12072-024-10731-0","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T08:02:15Z","timestamp":1729065735000},"page":"1740-1755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research"],"prefix":"10.1007","volume":"18","author":[{"given":"Maito","family":"Suoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Esmaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Eslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8421-5476","authenticated-orcid":false,"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"issue":"6","key":"10731_CR1","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889\u2013919","journal-title":"Hepatol Int"},{"issue":"1","key":"10731_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209","journal-title":"J Hepatol"},{"issue":"7","key":"10731_CR3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999\u20132014","journal-title":"Gastroenterology"},{"issue":"4","key":"10731_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"XD Zhou","year":"2023","unstructured":"Zhou XD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17(4):773\u2013791","journal-title":"Hepatol Int"},{"issue":"3","key":"10731_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.21037\/hbsn-22-421","volume":"12","author":"DQ Sun","year":"2023","unstructured":"Sun DQ, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surg Nutr. 2023;12(3):386\u2013403","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"6","key":"10731_CR6","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14478","volume":"40","author":"Y Fouad","year":"2020","unstructured":"Fouad Y, et al. What\u2019s in a name? Renaming \u201cNAFLD\u201d to \u201cMAFLD.\u201d Liver Int. 2020;40(6):1254\u20131261","journal-title":"Liver Int"},{"issue":"7","key":"10731_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41575-020-0316-6","volume":"17","author":"H Tilg","year":"2020","unstructured":"Tilg H, et al. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol. 2020;17(7):387\u2013388","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10731_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S2468-1253(20)30294-6","volume":"6","author":"G Shiha","year":"2021","unstructured":"Shiha G, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol. 2021;6(1):73\u201379","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10731_CR9","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.31420","volume":"73","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73(3):1194\u20131198","journal-title":"Hepatology"},{"issue":"1","key":"10731_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S2468-1253(20)30213-2","volume":"6","author":"G Shiha","year":"2021","unstructured":"Shiha G, et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol. 2021;6(1):57\u201364","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10731_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2468-1253(20)30340-X","volume":"6","author":"N Mendez-Sanchez","year":"2021","unstructured":"Mendez-Sanchez N, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6(1):65\u201372","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10731_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jhep.2021.05.003","volume":"75","author":"Y Nan","year":"2021","unstructured":"Nan Y, et al. The Chinese society of hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021;75(2):454\u2013461","journal-title":"J Hepatol"},{"issue":"5","key":"10731_CR13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","volume":"7","author":"N Mendez-Sanchez","year":"2022","unstructured":"Mendez-Sanchez N, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388\u2013390","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10731_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/MOG.0000000000000823","volume":"38","author":"J Alharthi","year":"2022","unstructured":"Alharthi J, et al. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38(3):251\u2013260","journal-title":"Curr Opin Gastroenterol"},{"issue":"1","key":"10731_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MCG.0000000000001459","volume":"55","author":"S Hamid","year":"2021","unstructured":"Hamid S, et al. WGO guidance for the care of patients with COVID-19 and liver disease. J Clin Gastroenterol. 2021;55(1):1\u201311","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10731_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41574-020-00462-1","volume":"17","author":"N Stefan","year":"2021","unstructured":"Stefan N, et al. Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17(3):135\u2013149","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10731_CR17","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u20131986","journal-title":"Hepatology"},{"key":"10731_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","volume":"133","author":"N Donthu","year":"2021","unstructured":"Donthu N, et al. How to conduct a bibliometric analysis: An overview and guidelines. J Bus Res. 2021;133:285\u2013296","journal-title":"J Bus Res"},{"key":"10731_CR19","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1186\/s40064-015-1542-1","volume":"4","author":"TS Zhang","year":"2015","unstructured":"Zhang TS, et al. Global publication trends and research hotspots of nonalcoholic fatty liver disease: a bibliometric analysis and systematic review. Springerplus. 2015;4:776","journal-title":"Springerplus"},{"key":"10731_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.990953","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, et al. Emerging trends and hotspots in the links between the gut microbiota and MAFLD from 2002 to 2021: a bibliometric analysis. Front Endocrinol. 2022;13: 990953","journal-title":"Front Endocrinol"},{"key":"10731_CR21","doi-asserted-by":"publisher","first-page":"1078149","DOI":"10.3389\/fendo.2023.1078149","volume":"14","author":"Y Liao","year":"2023","unstructured":"Liao Y, et al. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: a bibliometric analysis. Front Endocrinol. 2023;14:1078149","journal-title":"Front Endocrinol"},{"key":"10731_CR22","doi-asserted-by":"publisher","first-page":"1231520","DOI":"10.3389\/fendo.2023.1231520","volume":"14","author":"K Luo","year":"2023","unstructured":"Luo K, et al. Study on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis. Front Endocrinol (Lausanne). 2023;14:1231520","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"37","key":"10731_CR23","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.3748\/wjg.v29.i37.5339","volume":"29","author":"JJ Dai","year":"2023","unstructured":"Dai JJ, et al. Global trends and hotspots of treatment for nonalcoholic fatty liver disease: a bibliometric and visualization analysis (2010\u20132023). World J Gastroenterol. 2023;29(37):5339\u20135360","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10731_CR24","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","volume":"11","author":"M Aria","year":"2017","unstructured":"Aria M, et al. bibliometrix\u202f: an R-tool for comprehensive science mapping analysis. J Informet. 2017;11(4):959\u2013975","journal-title":"J Informet"},{"issue":"2","key":"10731_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.joi.2016.02.007","volume":"10","author":"L Waltman","year":"2016","unstructured":"Waltman L. A review of the literature on citation impact indicators. J Inform. 2016;10(2):365\u2013391","journal-title":"J Inform"},{"issue":"4","key":"10731_CR26","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.joi.2016.10.006","volume":"10","author":"A Perianes-Rodriguez","year":"2016","unstructured":"Perianes-Rodriguez A, et al. Constructing bibliometric networks: a comparison between full and fractional counting. J Inform. 2016;10(4):1178\u20131195","journal-title":"J Inform"},{"issue":"3","key":"10731_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.socnet.2010.03.006","volume":"32","author":"T Opsahl","year":"2010","unstructured":"Opsahl T, et al. Node centrality in weighted networks: Generalizing degree and shortest paths. Soc Netw. 2010;32(3):245\u2013251","journal-title":"Soc Netw"},{"issue":"1","key":"10731_CR28","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1038\/s41598-019-41695-z","volume":"9","author":"VA Traag","year":"2019","unstructured":"Traag VA, et al. From Louvain to Leiden: guaranteeing well-connected communities. Sci Rep. 2019;9(1):5233","journal-title":"Sci Rep"},{"key":"10731_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.761538","volume":"8","author":"W Qu","year":"2021","unstructured":"Qu W, et al. Liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies. Front Med. 2021;8: 761538","journal-title":"Front Med"},{"issue":"1","key":"10731_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/CM9.0000000000001263","volume":"134","author":"YX Xian","year":"2020","unstructured":"Xian YX, et al. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. 2020;134(1):8\u201319","journal-title":"Chin Med J"},{"issue":"6","key":"10731_CR31","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.dsx.2020.09.026","volume":"14","author":"MS Kuchay","year":"2020","unstructured":"Kuchay MS, et al. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr. 2020;14(6):1875\u20131887","journal-title":"Diabetes Metab Syndr"},{"issue":"7","key":"10731_CR32","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.tem.2021.04.008","volume":"32","author":"S Lim","year":"2021","unstructured":"Lim S, et al. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500\u2013514","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"10731_CR33","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14548","volume":"40","author":"S Lin","year":"2020","unstructured":"Lin S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082\u20132089","journal-title":"Liver Int"},{"key":"10731_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154244","volume":"108","author":"KI Zheng","year":"2020","unstructured":"Zheng KI, et al. Letter to the editor: obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108: 154244","journal-title":"Metabolism"},{"issue":"12","key":"10731_CR35","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/liv.14675","volume":"40","author":"S Yamamura","year":"2020","unstructured":"Yamamura S, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40(12):3018\u20133030","journal-title":"Liver Int"},{"issue":"3","key":"10731_CR36","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","volume":"53","author":"A Remmerie","year":"2020","unstructured":"Remmerie A, et al. Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver. Immunity. 2020;53(3):641\u2013657","journal-title":"Immunity"},{"issue":"10","key":"10731_CR37","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, et al. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide Cohort Study. Clin Gastroenterol Hepatol. 2021;19(10):2138\u20132147","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10731_CR38","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","volume":"75","author":"D Kim","year":"2021","unstructured":"Kim D, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75(6):1284\u20131291","journal-title":"J Hepatol"},{"key":"10731_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154433","volume":"115","author":"DQ Sun","year":"2021","unstructured":"Sun DQ, et al. MAFLD and risk of CKD. Metabolism. 2021;115: 154433","journal-title":"Metabolism"},{"issue":"8","key":"10731_CR40","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/gutjnl-2020-321611","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69(8):1545\u20131547","journal-title":"Gut"},{"issue":"10","key":"10731_CR41","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.cgh.2020.10.046","volume":"19","author":"VW Wong","year":"2021","unstructured":"Wong VW, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19(10):2161\u20132171","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10731_CR42","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.13685","volume":"51","author":"T Tsutsumi","year":"2021","unstructured":"Tsutsumi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115\u20131128","journal-title":"Hepatol Res"},{"issue":"10","key":"10731_CR43","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","volume":"19","author":"VH Nguyen","year":"2021","unstructured":"Nguyen VH, et al. Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172\u20132181","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10731_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245762","volume":"16","author":"MA Niriella","year":"2021","unstructured":"Niriella MA, et al. Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study. PLoS ONE. 2021;16(2): e0245762","journal-title":"PLoS ONE"},{"key":"10731_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.693507","volume":"8","author":"Q Huang","year":"2021","unstructured":"Huang Q, et al. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-results from NHANES III. Front Med. 2021;8: 693507","journal-title":"Front Med"},{"issue":"2","key":"10731_CR46","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s12072-021-10157-y","volume":"15","author":"GTS Guerreiro","year":"2021","unstructured":"Guerreiro GTS, et al. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int. 2021;15(2):380\u2013391","journal-title":"Hepatol Int"},{"issue":"3","key":"10731_CR47","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.cgh.2021.11.038","volume":"21","author":"GEH Lim","year":"2023","unstructured":"Lim GEH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(3):619\u2013629","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10731_CR48","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/hep.32131","volume":"75","author":"LA van Kleef","year":"2022","unstructured":"van Kleef LA, et al. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: the Rotterdam Study. Hepatology. 2022;75(2):419\u2013429","journal-title":"Hepatology"},{"issue":"1","key":"10731_CR49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year Cohort study in China. J Clin Endocrinol Metab. 2022;107(1):88\u201397","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10731_CR50","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","volume":"107","author":"KE Chan","year":"2022","unstructured":"Chan KE, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691\u20132700","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10731_CR51","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/j.cgh.2021.02.030","volume":"20","author":"J Liu","year":"2022","unstructured":"Liu J, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20(3):e573\u2013e582","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10731_CR52","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12876-021-01782-w","volume":"21","author":"YL Chen","year":"2021","unstructured":"Chen YL, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 2021;21(1):212","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10731_CR53","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/MEG.0000000000001946","volume":"34","author":"F Eren","year":"2022","unstructured":"Eren F, et al. Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals. Eur J Gastroenterol Hepatol. 2022;34(1):98\u2013103","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"10731_CR54","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41575-022-00635-5","volume":"19","author":"M Eslam","year":"2022","unstructured":"Eslam M, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638\u2013651","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10731_CR55","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jhep.2021.10.016","volume":"76","author":"B Guo","year":"2022","unstructured":"Guo B, et al. Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease. J Hepatol. 2022;76(3):518\u2013525","journal-title":"J Hepatol"},{"issue":"34","key":"10731_CR56","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.3748\/wjg.v27.i34.5753","volume":"27","author":"YL Wu","year":"2021","unstructured":"Wu YL, et al. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol. 2021;27(34):5753\u20135763","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10731_CR57","first-page":"37","volume":"2","author":"Y Yilmaz","year":"2021","unstructured":"Yilmaz Y, et al. The prevalence of metabolic-associated fatty liver disease in the Turkish population: a multicenter study. Hepatol Forum. 2021;2(2):37\u201342","journal-title":"Hepatol Forum"},{"issue":"8","key":"10731_CR58","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.3390\/ijms22084156","volume":"22","author":"Y Sakurai","year":"2021","unstructured":"Sakurai Y, et al. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021;22(8):4156","journal-title":"Int J Mol Sci"},{"key":"10731_CR59","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2147\/RMHP.S285880","volume":"14","author":"J Huang","year":"2021","unstructured":"Huang J, et al. MAFLD criteria guide the subtyping of patients with fatty liver disease. Risk Manag Healthc Policy. 2021;14:491\u2013501","journal-title":"Risk Manag Healthc Policy"},{"key":"10731_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101238","volume":"50","author":"J Heeren","year":"2021","unstructured":"Heeren J, et al. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50: 101238","journal-title":"Mol Metab"},{"issue":"5","key":"10731_CR61","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/jcm10050924","volume":"10","author":"M Flisiak-Jackiewicz","year":"2021","unstructured":"Flisiak-Jackiewicz M, et al. From nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD)-new terminology in pediatric patients as a step in good scientific direction? J Clin Med. 2021;10(5):924","journal-title":"J Clin Med"},{"issue":"8","key":"10731_CR62","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/apt.15989","volume":"52","author":"P O'Gorman","year":"2020","unstructured":"O\u2019Gorman P, et al. Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. Aliment Pharmacol Ther. 2020;52(8):1387\u20131398","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10731_CR63","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.4103\/jfmpc.jfmpc_412_21","volume":"10","author":"A Tomar","year":"2021","unstructured":"Tomar A, et al. Association of obstructive sleep apnea with nocturnal hypoxemia in metabolic-associated fatty liver disease patients: a cross-sectional analysis of record-based data. J Family Med Prim Care. 2021;10(8):3105\u20133110","journal-title":"J Family Med Prim Care"},{"issue":"3","key":"10731_CR64","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2020.04.027","volume":"73","author":"YJ Zhou","year":"2020","unstructured":"Zhou YJ, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol. 2020;73(3):719\u2013721","journal-title":"J Hepatol"},{"issue":"2","key":"10731_CR65","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.dld.2020.09.007","volume":"53","author":"L Pan","year":"2021","unstructured":"Pan L, et al. Metabolic associated fatty liver disease increases the severity of COVID-19: a meta-analysis. Dig Liver Dis. 2021;53(2):153\u2013157","journal-title":"Dig Liver Dis"},{"issue":"9","key":"10731_CR66","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1111\/liv.14575","volume":"40","author":"YJ Zhou","year":"2020","unstructured":"Zhou YJ, et al. Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver Int. 2020;40(9):2160\u20132163","journal-title":"Liver Int"},{"issue":"1","key":"10731_CR67","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/jgh.15112","volume":"36","author":"F Gao","year":"2021","unstructured":"Gao F, et al. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. J Gastroenterol Hepatol. 2021;36(1):204\u2013207","journal-title":"J Gastroenterol Hepatol"},{"key":"10731_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.626425","volume":"8","author":"PJ Hegyi","year":"2021","unstructured":"Hegyi PJ, et al. Metabolic associated fatty liver disease is associated with an increased risk of severe COVID-19: a systematic review with meta-analysis. Front Med. 2021;8: 626425","journal-title":"Front Med"},{"issue":"16","key":"10731_CR69","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3748\/wjg.v26.i16.1861","volume":"26","author":"J Alharthi","year":"2020","unstructured":"Alharthi J, et al. Macrophages in metabolic associated fatty liver disease. World J Gastroenterol. 2020;26(16):1861\u20131878","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10731_CR70","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.dsx.2020.06.013","volume":"14","author":"P Sharma","year":"2020","unstructured":"Sharma P, et al. Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19. Diabetes Metab Syndr. 2020;14(5):825\u2013827","journal-title":"Diabetes Metab Syndr"},{"issue":"10","key":"10731_CR71","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1097\/MCG.0000000000001605","volume":"55","author":"Z Tao","year":"2021","unstructured":"Tao Z, et al. Risk of severe COVID-19 increased by metabolic dysfunction-associated fatty liver disease: a meta-analysis. J Clin Gastroenterol. 2021;55(10):830\u2013835","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10731_CR72","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/liv.15188","volume":"42","author":"TM Farahat","year":"2022","unstructured":"Farahat TM, et al. The paradigm shift from NAFLD to MAFLD: a global primary care viewpoint. Liver Int. 2022;42(6):1259\u20131267","journal-title":"Liver Int"},{"issue":"11","key":"10731_CR73","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S2468-1253(22)00041-3","volume":"7","author":"CW Spearman","year":"2022","unstructured":"Spearman CW, et al. Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2022;7(11):1036\u20131048","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10731_CR74","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6(10):864\u2013873","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10731_CR75","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1007\/s12072-024-10671-9","volume":"18","author":"SH Cho","year":"2024","unstructured":"Cho SH, et al. Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality: a nationwide study. Hepatol Int. 2024;18(4):1168\u20131177","journal-title":"Hepatol Int"},{"issue":"1","key":"10731_CR76","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gutjnl-2021-324915","volume":"72","author":"A Vitale","year":"2023","unstructured":"Vitale A, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002\u20132033: the ITA.LI.CA database. Gut. 2023;72(1):141\u2013152","journal-title":"Gut"},{"issue":"1","key":"10731_CR77","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/hep4.1606","volume":"5","author":"VL Chen","year":"2021","unstructured":"Chen VL, et al. Effects of cirrhosis and diagnosis scenario in metabolic-associated fatty liver disease-related hepatocellular carcinoma. Hepatol Commun. 2021;5(1):122\u2013132","journal-title":"Hepatol Commun"},{"issue":"2","key":"10731_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100231","volume":"3","author":"S Myers","year":"2021","unstructured":"Myers S, et al. NAFLD and MAFLD as emerging causes of HCC: a populational study. JHEP Rep. 2021;3(2): 100231","journal-title":"JHEP Rep"},{"issue":"9","key":"10731_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100810","volume":"5","author":"BG Song","year":"2023","unstructured":"Song BG, et al. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma. JHEP Rep. 2023;5(9): 100810","journal-title":"JHEP Rep"},{"issue":"3","key":"10731_CR80","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3350\/cmh.2024.0109","volume":"30","author":"H Crane","year":"2024","unstructured":"Crane H, et al. Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Clin Mol Hepatol. 2024;30(3):436\u2013448","journal-title":"Clin Mol Hepatol"},{"key":"10731_CR81","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0372","author":"T Nakamura","year":"2024","unstructured":"Nakamura T, et al. MAFLD Is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma. Clin Mol Hepatol. 2024. https:\/\/doi.org\/10.3350\/cmh.2024.0372","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10731_CR82","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejso.2021.07.015","volume":"48","author":"S Conci","year":"2022","unstructured":"Conci S, et al. Hepatectomy for metabolic associated fatty liver disease (MAFLD) related HCC: propensity case-matched analysis with viral- and alcohol-related HCC. Eur J Surg Oncol. 2022;48(1):103\u2013112","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10731_CR83","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/ijc.34637","volume":"153","author":"MN Kim","year":"2023","unstructured":"Kim MN, et al. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients. Int J Cancer. 2023;153(8):1448\u20131458","journal-title":"Int J Cancer"},{"issue":"5","key":"10731_CR84","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s12072-023-10545-6","volume":"17","author":"SC Huang","year":"2023","unstructured":"Huang SC, et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int. 2023;17(5):1139\u20131149","journal-title":"Hepatol Int"},{"issue":"2","key":"10731_CR85","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/hepr.13843","volume":"53","author":"S Shimose","year":"2023","unstructured":"Shimose S, et al. The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma. Hepatol Res. 2023;53(2):104\u2013115","journal-title":"Hepatol Res"},{"issue":"6","key":"10731_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100591","volume":"7","author":"M Rimini","year":"2022","unstructured":"Rimini M, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022;7(6): 100591","journal-title":"ESMO Open"},{"key":"10731_CR87","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2022.11.017","volume":"180","author":"A Casadei-Gardini","year":"2023","unstructured":"Casadei-Gardini A, et al. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer. 2023;180:9\u201320","journal-title":"Eur J Cancer"},{"key":"10731_CR88","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10692-4","author":"ME Argenziano","year":"2024","unstructured":"Argenziano ME, et al. Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients. Hepatol Int. 2024. https:\/\/doi.org\/10.1007\/s12072-024-10692-4","journal-title":"Hepatol Int"},{"issue":"4","key":"10731_CR89","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s12072-022-10362-3","volume":"16","author":"YC Zhang","year":"2022","unstructured":"Zhang YC, et al. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population. Hepatol Int. 2022;16(4):835\u2013845","journal-title":"Hepatol Int"},{"issue":"10","key":"10731_CR90","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/hepr.13808","volume":"52","author":"S Inamine","year":"2022","unstructured":"Inamine S, et al. Metabolic dysfunction-associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients. Hepatol Res. 2022;52(10):841\u2013858","journal-title":"Hepatol Res"},{"issue":"8","key":"10731_CR91","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/hepr.13906","volume":"53","author":"T Miwa","year":"2023","unstructured":"Miwa T, et al. Impact of body fat accumulation on metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults. Hepatol Res. 2023;53(8):691\u2013700","journal-title":"Hepatol Res"},{"issue":"5","key":"10731_CR92","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s12072-023-10558-1","volume":"17","author":"J Xie","year":"2023","unstructured":"Xie J, et al. A simpler definition of MAFLD precisely predicts incident metabolic diseases: a 7-year cohort study. Hepatol Int. 2023;17(5):1182\u20131191","journal-title":"Hepatol Int"},{"issue":"6","key":"10731_CR93","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s12072-021-10252-0","volume":"15","author":"HH Liu","year":"2021","unstructured":"Liu HH, et al. Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. Hepatol Int. 2021;15(6):1337\u20131346","journal-title":"Hepatol Int"},{"issue":"3","key":"10731_CR94","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s12072-023-10486-0","volume":"17","author":"S Chen","year":"2023","unstructured":"Chen S, et al. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants. Hepatol Int. 2023;17(3):595\u2013605","journal-title":"Hepatol Int"},{"key":"10731_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154955","volume":"127","author":"Z Liu","year":"2022","unstructured":"Liu Z, et al. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metabolism. 2022;127: 154955","journal-title":"Metabolism"},{"issue":"2","key":"10731_CR96","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/hepr.13973","volume":"54","author":"S Fukunaga","year":"2024","unstructured":"Fukunaga S, et al. Impact of non-obese metabolic dysfunction-associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: a multicenter study. Hepatol Res. 2024;54(2):201\u2013212","journal-title":"Hepatol Res"},{"issue":"6","key":"10731_CR97","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/hepr.14010","volume":"54","author":"T Nakane","year":"2024","unstructured":"Nakane T, et al. Impact of metabolic dysfunction-associated fatty liver disease on the incidence of Helicobacter pylori-negative gastric cancer. Hepatol Res. 2024;54(6):540\u2013550","journal-title":"Hepatol Res"},{"issue":"1","key":"10731_CR98","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000435","volume":"13","author":"H Lee","year":"2022","unstructured":"Lee H, et al. Metabolic dysfunction-associated fatty liver disease increases colon cancer risk: a nationwide Cohort Study. Clin Transl Gastroenterol. 2022;13(1): e00435","journal-title":"Clin Transl Gastroenterol"},{"issue":"7","key":"10731_CR99","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1210\/clinem\/dgad016","volume":"108","author":"YL Chen","year":"2023","unstructured":"Chen YL, et al. Impact of thyroid function on the prevalence and mortality of metabolic dysfunction-associated fatty liver disease. J Clin Endocrinol Metab. 2023;108(7):e434\u2013e443","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10731_CR100","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/hepr.13795","volume":"52","author":"S Fukunaga","year":"2022","unstructured":"Fukunaga S, et al. Lean\/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis. Hepatol Res. 2022;52(8):699\u2013711","journal-title":"Hepatol Res"},{"issue":"1","key":"10731_CR101","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13098-022-00887-w","volume":"14","author":"T Tsutsumi","year":"2022","unstructured":"Tsutsumi T, et al. MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men. Diabetol Metab Syndr. 2022;14(1):115","journal-title":"Diabetol Metab Syndr"},{"issue":"5","key":"10731_CR102","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3390\/nu15051123","volume":"15","author":"T Tsutsumi","year":"2023","unstructured":"Tsutsumi T, et al. The inter-organ crosstalk reveals an inevitable link between MAFLD and extrahepatic diseases. Nutrients. 2023;15(5):1123","journal-title":"Nutrients"},{"issue":"5","key":"10731_CR103","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/hepr.13706","volume":"52","author":"T Kawaguchi","year":"2022","unstructured":"Kawaguchi T, et al. MAFLD: renovation of clinical practice and disease awareness of fatty liver. Hepatol Res. 2022;52(5):422\u2013432","journal-title":"Hepatol Res"},{"issue":"6","key":"10731_CR104","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams LA, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138\u20131153","journal-title":"Gut"},{"issue":"1","key":"10731_CR105","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12072-023-10620-y","volume":"18","author":"MM Ramirez-Mejia","year":"2024","unstructured":"Ramirez-Mejia MM, et al. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification? Hepatol Int. 2024;18(1):168\u2013178","journal-title":"Hepatol Int"},{"issue":"3","key":"10731_CR106","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1007\/s12072-024-10673-7","volume":"18","author":"Z Pan","year":"2024","unstructured":"Pan Z, et al. MAFLD identifies patients with significant hepatic fibrosis better than MASLD. Hepatol Int. 2024;18(3):964\u2013972","journal-title":"Hepatol Int"},{"issue":"7","key":"10731_CR107","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/liv.15931","volume":"44","author":"Z Pan","year":"2024","unstructured":"Pan Z, et al. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int. 2024;44(7):1567\u20131574","journal-title":"Liver Int"},{"issue":"5","key":"10731_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2024.101512","volume":"29","author":"Z Pan","year":"2024","unstructured":"Pan Z, et al. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease. Ann Hepatol. 2024;29(5): 101512","journal-title":"Ann Hepatol"},{"key":"10731_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155800","volume":"153","author":"HJ Choe","year":"2024","unstructured":"Choe HJ, et al. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up. Metabolism. 2024;153: 155800","journal-title":"Metabolism"},{"key":"10731_CR110","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000925","author":"M Kwak","year":"2024","unstructured":"Kwak M, et al. MASLD\/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population-based study with 26.7 years of follow-up. Hepatology. 2024. https:\/\/doi.org\/10.1097\/HEP.0000000000000925","journal-title":"Hepatology"},{"issue":"11","key":"10731_CR111","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1111\/liv.15695","volume":"43","author":"S Ciardullo","year":"2023","unstructured":"Ciardullo S, et al. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;43(11):2425\u20132433","journal-title":"Liver Int"},{"issue":"4","key":"10731_CR112","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/liv.15856","volume":"44","author":"R Song","year":"2024","unstructured":"Song R, et al. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver Int. 2024;44(4):1051\u20131060","journal-title":"Liver Int"},{"issue":"1","key":"10731_CR113","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/apt.18011","volume":"60","author":"D Kim","year":"2024","unstructured":"Kim D, et al. Steatotic liver disease-associated all-cause\/cause-specific mortality in the United States. Aliment Pharmacol Ther. 2024;60(1):33\u201342","journal-title":"Aliment Pharmacol Ther"},{"key":"10731_CR114","doi-asserted-by":"publisher","unstructured":"Hoang T, et al. Evaluation of nomenclature of fatty liver disease in association with hepatocellular carcinoma: a 15.5-year Cohort Study in Korea. 2024. https:\/\/doi.org\/10.2139\/ssrn.4879244.","DOI":"10.2139\/ssrn.4879244"},{"issue":"6","key":"10731_CR115","doi-asserted-by":"publisher","first-page":"E157","DOI":"10.1097\/HEP.0000000000000745","volume":"79","author":"Y Fouad","year":"2024","unstructured":"Fouad Y, et al. Letter to the editor: how F to S turned the premature to be mature? Hepatology. 2024;79(6):E157\u2013E158","journal-title":"Hepatology"},{"issue":"1","key":"10731_CR116","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/j.jhep.2024.03.007","volume":"81","author":"MM Ramirez-Mejia","year":"2024","unstructured":"Ramirez-Mejia MM, et al. The MAFLD and MASLD conundrum: Is it reinvention of the wheel? J Hepatol. 2024;81(1):e22\u2013e23","journal-title":"J Hepatol"},{"issue":"2","key":"10731_CR117","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1016\/j.jhep.2023.08.027","volume":"80","author":"MG Sanal","year":"2024","unstructured":"Sanal MG. Is the change from NAFLD to MASLD driven by political correctness? J Hepatol. 2024;80(2):e74\u2013e76","journal-title":"J Hepatol"},{"issue":"5","key":"10731_CR118","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/j.jhep.2024.01.012","volume":"80","author":"A Lonardo","year":"2024","unstructured":"Lonardo A, et al. Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature. J Hepatol. 2024;80(5):e192\u2013e194","journal-title":"J Hepatol"},{"issue":"4","key":"10731_CR119","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/liv.14788","volume":"41","author":"M Clayton","year":"2021","unstructured":"Clayton M, et al. From NAFLD to MAFLD: nurse and allied health perspective. Liver Int. 2021;41(4):683\u2013691","journal-title":"Liver Int"},{"issue":"6","key":"10731_CR120","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.jhep.2022.08.027","volume":"77","author":"G Shiha","year":"2022","unstructured":"Shiha G, et al. MAFLD 2022: An ELPA\/ALPA\/EASO-ECPO joint statement on disease stigma. J Hepatol. 2022;77(6):1717\u20131719","journal-title":"J Hepatol"},{"issue":"3","key":"10731_CR121","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jhep.2023.11.004","volume":"80","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, et al. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2024;80(3):419\u2013430","journal-title":"J Hepatol"},{"key":"10731_CR122","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000886","author":"M Alboraie","year":"2024","unstructured":"Alboraie M, et al. Letter to the Editor: MAFLD versus MASLD-Which is more appropriate from a global perspective? Hepatology. 2024. https:\/\/doi.org\/10.1097\/HEP.0000000000000886","journal-title":"Hepatology"},{"issue":"5","key":"10731_CR123","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/j.jhep.2024.01.033","volume":"80","author":"Y Fouad","year":"2024","unstructured":"Fouad Y, et al. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition. J Hepatol. 2024;80(5):e194\u2013e197","journal-title":"J Hepatol"},{"key":"10731_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.05.031","author":"L Miao","year":"2024","unstructured":"Miao L, et al. \u201cFatty\u201d or \u201csteatotic\u201d: position statement from a linguistic perspective by the Chinese-speaking community. J Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.jhep.2024.05.031","journal-title":"J Hepatol"},{"issue":"4","key":"10731_CR125","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3163\/1536-5050.103.4.014","volume":"103","author":"CW Belter","year":"2015","unstructured":"Belter CW. Bibliometric indicators: opportunities and limits. J Med Libr Assoc. 2015;103(4):219\u2013221","journal-title":"J Med Libr Assoc"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10731-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10731-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10731-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T05:41:41Z","timestamp":1733895701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10731-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":125,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10731"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10731-0","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maito Suoh, Saeed Esmaili, Mohammed Eslam, and Jacob George declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}}]}}